Financial Daily from THE HINDU group of publications
Saturday, Sep 11, 2004
Financial Daily from THE HINDU group of publications Saturday, Sep 11, 2004 |
||
|
|
||
|
Corporate
-
Announcements Tentative nod for Ranbaxy drug Our Bureau
NEW DELHI: Ranbaxy Laboratories Ltd has received tentative approval from the US Food and Drug Administration (US FDA) to manufacture and market Levofloxacin tablets in 250 mg, 500 mg and 750 mg dosage used for the treatment of infections. The total market for Levofloxacin tablets is $1.27 billion and is growing at 18 per cent. Levofloxacin is used for treatment of a wide range of infections caused in the skin, urinary tract, bronchitis and even during pneumonia. "We are delighted to receive this tentative approval for a product that has both utility and value in the management of patients suffering from bacterial infections. We will launch Levofloxacin tablets at the time the final product approval is received from the USFDA," said Mr Jim Meehan, Vice-President (Sales & Marketing) of Ranbaxy Pharmaceuticals Inc.
More Stories on : Announcements | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|